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Nephronophthisis (NPH) is the most common monogenic cause of renal failure in
children. Treatment options are limited to dialysis and transplantation. Therapeutics to
significantly delay or prevent end-stage renal disease (ESRD) in children are currently not
available. In the Dutch-Anglo KOUNCIL (Kidney-Oriented UNderstanding of correcting
CILiopathies) consortium, several groups and specialties united to perform scientific
groundwork with the aim to develop genetic and therapeutic personalized care for NPH
patients. At the start of this consortium, a genetic diagnosis for NPH was available
for only 30–40% of patients, which improved to 50–60% during the course of the
4-year KOUNCIL project. Other major accomplishments of the consortium were (1) the
establishment of a Dutch renal ciliopathy patient database with genotype and phenotype
data; (2) composition of a proteomics-based integrated network of protein modules
disrupted in NPH; (3) the development of non-invasive, urine-based assays that allow
functional assessment of genomic variants in NPH and of therapeutic efficiency of drugs;
and (4) chemical screening toward the identification of compounds that delay or prevent
disease progression in NPH, which resulted in four potential medical interventions for
NPH. In conclusion, the KOUNCIL consortium effectively channeled complementary
approaches to broaden our understanding of NPH pathogenesis, resulted in 54
publications, improvement of genome diagnostics for NPH patients, awareness in the
nephrology and clinical genetics communities for NPH, and new avenues for patient
management.
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INTRODUCTION
Nephronophthisis (NPH; OMIM Phenotypic Series PS256100) is an autosomal recessive,
genetically heterogeneous disorder that results in chronic renal disease in children and
young adults (1). NPH is initially characterized by polydipsia and polyuria. Progression
of the disease is characterized by renal interstitial fibrosis, tubular basement membrane
disruption, and—in a subset of cases—renal cyst formation, eventually leading to renal failure.
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NPH can occur as an isolated disorder but is also often
accompanied by a variety of extrarenal manifestations such
as in Senior-Løken-, Joubert-, Bardet-Biedl-, Meckel-Gruber-,
Jeune-, Short-Rib-Polydactyly-, and Sensenbrenner syndromes.
These disorders overlap phenotypically, as well as genetically
and functionally. All are thought to result from defective
ciliary signaling, and are classified as renal ciliopathies or
nephronophthisis-related ciliopathies (NPH-RCs). Although
NPH patients are usually diagnosed when renal failure has
developed, NPH patients typically experience a 5–10-year period
between diagnosis and renal replacement therapy, which offers
a therapeutic window of opportunity. Currently, no medical
interventions are available for NPH patients. We anticipate that
the identified molecular defect in each patient will ultimately
steer the development and use of personalized therapies (2).
Gene identification is essential for development of
personalized therapies. However, genetic causes of NPH
are unknown in∼50% of cases (3, 4). Twenty genes are known to
date to be mutated in NPH. The vast majority of gene mutations
results in loss-of-function of proteins that are important for
ciliary architecture or regulation of signaling cascades. Cilia are
the tail-like microtubule-based protrusions from the plasma
membrane that reside on the apical surface of virtually every
vertebrate cell, including renal tubular cells. Cilia act as the cell’s
antenna by sensing the extracellular environment through an
array of specific receptors and transmitting a signal response
to the cell that reacts upon the signal. Ciliary gene disruption
can disrupt cilia-dependent signaling cascades, which may lead
to apoptosis and misaligned cell division (5). This results in
heterogeneous phenotypes that affect multiple organs, including
kidneys (6).
Despite steady progress in gene discovery over the past
decade, a significant number of genes mutated in NPH still
await identification because a significant proportion of NPH
cases remains unexplained. To address this issue and advance
NPH research and diagnostics collectively, our research groups
united in a Dutch-Anglo consortium, funded by the Dutch
Kidney Foundation. In this review, we aim to demonstrate
the value of synergistic consortia in obtaining the critical
mass required for patient cohort recruitment, while combining
complementary expertise to work toward gene identification and
targeted therapies for NPH.
THE KOUNCIL CONSORTIUM
The KOUNCIL (Kidney-Oriented UNderstanding of correcting
CILiopathies) consortium was founded to perform scientific
groundwork for the improvement of personalized care for
NPH patients. Our consortium augmented the individual
expertise of the collaborating workgroups toward reaching the
challenging goals. The consortium included research groups with
established expertise in renal ciliopathy research and diagnostics,
including clinical geneticists, pediatric nephrologists, molecular
biologists, cell biologists, and bioinformaticians (Figure 1). The
international scientific advisory board of the Dutch Kidney
Foundation reviewed and supported the consortium, and a
tailored internal scientific advisory board reviewed our progress
and suggested solutions to problems encountered.
We designed and conducted an integrated work plan
aimed to (1) identify novel genes associated with NPH and
related disorders by using next generation sequencing (NGS)
approaches, (2) gain insights in genotype-phenotype relations
through the setup and analysis of a renal ciliopathy database,
(3) increase our understanding of the composition and function
NPH-related proteinmodules in the ciliary proteome and explore
mutational effects by state-of-the-art proteomics, and (4) initiate
the development of targeted therapies to delay or prevent renal
failure in NPH patients by drug screening in zebrafish and 3D
culturing of cells derived from patients’ urine samples.
By bringing together the three university medical centers
in our project we maximized patient inclusion. This was an
important aspect of our study as NPH and -related disorders are
individually rare. Combining our efforts has led to significant
conclusions and high impact findings. The interactions within
and between the different groups and work packages have
been very open and effective, and by connecting different
disciplines in the KOUNCIL project, a robust workflow could
be implemented in the clinic that results from this synergy. We
believe that without the close and successful collaboration within
the consortium, the results would have been less optimal.
RESULTS OF KOUNCIL
Patient Recruitment, Database Generation,
and Diagnostics
The success of research consortia relies heavily on patient
numbers, diagnostic accuracy, and deep-phenotyping of patients.
In KOUNCIL, we used the AGORA data- and biobank protocols
to systematically recruit and include patients (http://www.
agoraproject.nl) (7). Furthermore, we involved the professional
Society for Dutch Pediatric Nephrologists and requested
participation of pediatric nephrologists in recruiting patients for
the renal ciliopathy database. Patients were also directly informed
via the Dutch Kidney Patient Association and the KOUNCIL
website (http://www.kouncil.nl). Clinical data including renal
and extrarenal phenotypic information was obtained and
manually curated for inclusion in the renal ciliopathy database
(Figure 2). So far, 88 patients with NPH and -related disorders
have been included in our coded database. Inclusion is ongoing
and the database will be maintained as a resource during the
following years. The database is a valuable source of clinical
and genetic information, and is currently being assessed for
investigations on genotype-phenotype correlations to improve
early diagnosis, prognosis, and genetic counseling. Furthermore,
the database offers opportunities to match with other renal
ciliopathy databases such as the German language cohort
Nephreg (http://www.nephreg.de), and we hope to follow up on
that initiative.
We applied NGS approaches to identify causative genetic
defects in 50 patients with unexplained renal ciliopathies. These
methods include targeted gene panel sequencing and whole
exome sequencing that facilitate the parallel analysis of multiple
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FIGURE 1 | Overview of the KOUNCIL consortium work plan that aims to improve personalized diagnostics, counseling, and treatment for nephronophthisis (NPH)
patients. In work package 1 (WP1), genotypes and phenotypes were extensively studied and recorded in the nephronophthisis (NPH) database. In work package 2
(WP2), NPH protein modules were identified and NPH-related genes and gene variants were functionally characterized in vitro and in vivo. Work package 3 (WP3)
focused on therapy development by drug screening in zebrafish that displayed nephric cysts. NGS; next generation sequencing.
genes in one sequencing run in a cost- and time-efficient manner.
This has led to the identification and confirmation of multiple
genes for renal ciliopathy-related diseases: WDR60 (8), WDR34
(9), IFT172 (10), DCDC2 (11), CEP120 (12), ICK (13), EXTL3
(14), and TCTEX1D2 (15). Causal variant identification in new
and known genes resulted in a genetic diagnosis for 31 patients
from our cohort, who had not received a prior molecular
diagnosis. We have implemented renal ciliopathy-specific gene
screening in our genome diagnostic divisions and ensure high
sensitivity and optimal diagnostic yield by periodically updating
available tests.
Understanding Functional Defects
Underlying Renal Ciliopathies
Cilia are regulated by defined protein complexes, some of
which act as molecular machines (16). It is estimated that
1,000–2,000 proteins contribute to ciliary architecture or
signaling. Through large-scale interaction assays, many of
these proteins have been delineated in functional modules
that are interconnected. Disrupting ciliary protein-protein
interactions interferes with modules regulating cilia function.
Because different ciliopathies are characterized by multiple and
overlapping phenotypes, we hypothesized that there is also
overlap in the molecular defects and protein modules that are
disrupted in the different ciliopathies, including eye, brain, and
kidney abnormalities (Figure 3) (17). Work that was performed
prior to KOUNCIL suggested that proteomics-based dissection
of molecular modules can relate biological mechanisms to
specific genotypes in ciliopathy patients (18). Proof of principle
ignited our interest to expand this approach to renal ciliopathies.
Although our approach involving state-of-the art quantitative
proteomics such as Stable Isotope Labeling with Amino acids
in Cell culture (SILAC) combined with mass spectrometry
proved technically challenging and involved multiple rounds of
troubleshooting and adaptation, we were eventually successful
in increasing our understanding of the ciliary protein complexes
that are disturbed in NPH and allied ciliopathies (Figure 4 and
unpublished data), which is indispensable for the development
of targeted therapies (17, 18). Another lesson learned was
that patients remain their own best model of disease, since
patient cells such as urine-derived renal epithelial cells (URECs)
and fibroblasts delivered the most relevant information about
possible pathogenic effects of detected genomic variation and
more generally, mechanisms of disease (Figure 4) (20). Thus,
implementation of the developed non-invasive methods for
patient-derived cell investigations has proven to be tremendously
useful in diagnostics for renal diseases and therapy development.
Advancing Therapeutics for NPH
Since there is no targeted cure for NPH, research toward the
development of therapies that slow renal disease progression in
NPH patients is warranted. We aimed to identify drugs that
delay or prevent renal cyst formation, and used zebrafish embryos
with pronephric cysts for a high-throughput drug screen to
achieve this goal. We first developed a robust zebrafish model for
NPH, using both morpholinos and CRISPR/Cas9 gene editing
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FIGURE 2 | Screenshots from parts of the nephronophthisis database. Numbers indicate the number of fields attributed to a specific theme.
FIGURE 3 | Schematic representation of understanding proteomic modules underlying ciliopathies. By performing systematic agnostic proteomic profiling of protein
complexes, it is possible to distinguish and find overlap in the disrupted protein modules in ciliopathies, featuring retinal degeneration, brain malformation, and/or renal
ciliopathies.
technologies. A popular drug screening strategy is repurposing,
whereby already FDA-approved drugs are investigated for new
uses. We hypothesized that such a strategy is likely effective
toward the identification of drugs that slow renal failure in NPH
as it would allow a fast conversion from drug identification to
actual clinical use. As such, we tested a library of FDA-approved
compounds for inhibitory effects on renal cystogenesis. Two
approaches were taken to screen for effective compounds. First,
we performed a screen of 640 drugs in zebrafish embryos with
NPH, which was a non-hypothesis driven approach. Secondly,
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FIGURE 4 | Defective retrograde transport in urine-derived cells from a
Mainzer-Saldino syndrome patient. URECs derived from a patient (referred to
as “patient” or “II-3”) with compound heterozygous variants in IFT140 (one
pathogenic frameshift and one missense variant of uncertain significance),
were compared to URECs from three control individuals (C1-3). (A) URECs
stained for ciliary marker acetylated-α-tubulin (red) and RPGRIP1L (green). (B)
Analysis of retrograde transport in controls, healthy family members (I-1, I-2,
and II-2) and patient (II-3) URECs. Cilia were visualized with
acetylated-α-tubulin (red) and RPGRIP1L (pink). The cells were analyzed for the
presence of IFT88 (green) accumulation at the ciliary tip. Patient II-3 showed a
significant tip accumulation of IFT88 in 41% of the cells (Fisher’s exact
two-tailed test showed a p < 0.0001 when comparing the cells of the patient
to those of the controls). Scale bar represents 5µm. (C) A schematic overview
of the cilium in controls and in the patient with pathogenic variants in IFT140.
The control shows normal intraflagellar transport with the IFT-B complex
transporting proteins from the base of the cilium to the tip (axoneme is shown
in red and the transition zone marks the base of the cilium in pink) and the
IFT-A complex transporting proteins back down to the base. The image shows
defective retrograde transport leading to an abnormal bulge at the ciliary tip,
which is filled with IFT-B proteins. This image was adapted from Oud et al. (19).
https://ciliajournal.biomedcentral.com/articles/10.1186/s13630-018-0055-2.
we extensively examined 14 therapies based on known beneficial
effects in polycystic kidney disease (PKD), as a candidate-selected
approach. From the second approach, four individual drugs and
one drug combination significantly rescued the NPH phenotype
in zebrafish embryos with acceptable toxicity profiles. These
drugs warrant further in vivo investigations for their potential in
modulating NPH-progression.
To further advance therapy development, a major effort
in KOUNCIL was the standardization of the use of URECs
in molecular and cellular diagnostics (20). The 3D culturing
of URECs resulted in clear characteristic growth patterns in
NPH patients. This allowed us to adapt a non-invasive drug
screening methodology in patient-derived 3D spheroids from
urine. Although expansion and validation of the URECs and 3D
models is ongoing, we are excited by the potential this patient-
centered approach offers.
ADVANCES FOR NPH-RC PATIENTS AND
THEIR FAMILIES
Our project advanced medical care for kidney patients and their
families. First, NGS-based methods that were implemented in
DNA diagnostics at the start of our project almost doubled
the diagnostic yield for NPH-RC. Secondly, NGS-based DNA
diagnostics for renal ciliopathies allow clinicians to make the
NPH diagnosis at a much earlier stage, which resolves the need
for invasive renal biopsies for diagnostic purposes. Third, a
solidified work flow has been implemented for renal ciliopathy
patients in our dedicated multidisciplinary outpatient clinics
for kidney diseases in the Radboud university medical center,
Nijmegen, The Netherlands and the University Medical Center
Utrecht, Utrecht, The Netherlands. In London, UK, multi-
disciplinary clinics for Bardet-Biedl Syndrome (BBS) patients
are provided. NPH-RC patients are seen by a nephrologist,
ophthalmologist, geneticist, dietician, general pediatricians,
endocrinologist (diabetes type II), and a clinical psychologist. The
aim is to provide a “one stop” visit to ensure that patients receive
specialized and expert attention and management. This should
result in a major change in how NPH and BBS is managed, with
a focus on diagnosis, early intervention and appropriate health
management. These multidisciplinary clinics form a role model
for other hospitals worldwide and will hopefully be more widely
implemented in the near future.
The fourth improvement in patient care results from the
setup of a renal ciliopathy database, which increased our insight
into the relation between genotypes and phenotypes of NPH-
RC patients. In the future, the database can be connected to
other databases and converted to an interactive, international
online registry. This will in turn allow for more refined insights
in genotype-phenotype correlations and prognosis (6). Finally,
we have developed a non-invasive protocol for research on renal
cells that does not require patients (and their parents) to visit
the hospital. In conclusion, KOUNCIL improved opportunities
for patient management, led to advancements in the diagnostic
trajectory and resulted in optimal genetic counseling for patients
and their families.
SCIENTIFIC IMPACT
KOUNCIL and KOUNCIL collaborations revealed several
new renal ciliopathy genes and molecular mechanisms of
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disease, which significantly improved the diagnostic yield for
NPH and related disorders as well as advanced knowledge of
ciliopathy pathophysiology. In combination with the phenotypic
characteristics sampled in our coded renal ciliopathy database,
the power of genotype-phenotype correlations for NPH is
just emerging and will require further prospective validation.
Continued genetic screening and ongoing deep phenotyping
of NPH-RC patients will further dissect these correlations,
ultimately improving patient counseling. Understanding
the impact of allelic variants from patients on disease
manifestations demands understanding of the extensive
molecular connectivity of cilium-directed pathways; to this
end, we have developed a proteomics-based approach to
evaluate the assembly defects of the ciliary transport particles
(IFT) in a subset of ciliopathy patients. Although ciliopathies
represent a class of rare pediatric diseases, through the
work of KOUNCIL, we have found novel insights into the
molecular mechanisms of chronic renal disease progression
widespread in the general population. Preliminary work
suggesting that cilia are key repressors of cellular fibrosis in
the kidney, will direct and further streamline future efforts
to develop therapeutic intervention with a focus on fibrosis
treatment.
It should be noted that development of methodologies
independent of animal experimentation are a priority for
most scientific bodies today. We have generated a robust
protocol growing renal cells from urine that is non-invasive
to patients, yet is patient-specific, and is amenable to
screening (20). We showed that functional tests in URECs
and CRISPR/Cas9-derived knockdown cells can more widely
clarify the pathogenicity of genetic variants of unknown
significance identified in NPH-RC patients. Growing 3D
spheroids from urine (“urinoids”) may also be appropriate for
variant interpretation and with appropriate quality assurance
measures, are potentially adaptable for diagnostic support
(21).
CONCLUSIONS
The KOUNCIL consortium, consisting of pediatric
nephrologists, clinical geneticists, molecular biologists and
bioinformaticians, provided a unique, coherent inter- and
transdisciplinary team to combat juvenile kidney failure. The
resulting five PhD theses from three centers in two countries
implicated the relevance of our consortium for the next
generation of renal clinicians and scientists, and will continue to
have a high impact on the renal field.
This consortium aimed to improve the understanding of
genetics and biology of renal ciliopathies with innovative NGS
and biochemical techniques, and set the first important steps
toward therapeutic approaches to delay the progressive
degenerative defects in the kidney. The results of this
consortium project have already significantly impacted
the clinical management of NPH-RC by improvements
in diagnosis, prognosis, and accuracy of genetic risk
assessment. Our project has provided us with optimal
preparations for the development and refinement of future
personalized therapies, and is a message of hope for
NPH patients for whom there is currently no satisfactory
treatment.
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